HER2-positive breast cancer: how treatment changes with the stage

Confirm the HER2 result used for the plan

HER2 testing uses immunohistochemistry and, when needed, an in situ hybridization test. The report should identify whether the cancer meets HER2-positive criteria. A low level of staining has different treatment implications from HER2-positive disease.

Ask for the complete report, including the score and any confirmatory test. If the cancer has recurred, the team may reassess receptor status on a metastatic sample. This helps avoid selecting a regimen from a result that no longer describes the current disease.

Sources and references: [1]

Early cancers do not all need the same intensity

The initial strategy considers tumor size, lymph nodes and general health. Some smaller, node-negative cancers can follow a less intensive systemic plan than higher-risk disease. Surgery and pathology help define the treatment needed afterward in suitable cases.

Ask what recurrence risk the proposed treatment is intended to reduce and which parts of the regimen are essential in your situation. Heart health, previous treatment and your priorities also belong in the discussion. A longer list of drugs is not automatically the most appropriate plan.

Sources and references: [1]

Treatment before surgery can guide later decisions

For selected higher-risk early HER2-positive cancers, anti-HER2 therapy with chemotherapy is given before surgery. The team assesses response during treatment and reviews the surgical plan. The final pathology then shows whether invasive cancer remains.

Ask when response imaging will happen and what information the surgeon needs before the operation. If you are seeking a second opinion during this phase, include baseline images and the exact medicines already received, not just the number of treatment sessions.

Sources and references: [1]

Why the postoperative medicine may change

Residual invasive disease after an appropriate neoadjuvant regimen can lead to a different postoperative anti-HER2 treatment discussion. Trastuzumab emtansine is one established example in this setting. A complete response also informs the remaining plan, but does not automatically end all treatment.

Request a review of the surgical pathology that connects the findings with the next recommendation. Ask how much further treatment is planned, what monitoring it needs and how radiation or endocrine therapy fits alongside it if relevant.

Sources and references: [1]

In advanced disease, the sequence matters

Metastatic treatment can include antibody combinations, ADCs and other HER2-directed approaches. Prior drugs, the interval since early treatment and the presence of brain metastases can change the preferred sequence. The team should explain why a particular option fits the current line of therapy.

Keep a record of prior trastuzumab, pertuzumab and any ADC exposure. A drug may be familiar from early treatment but have a different role in metastatic care. Ask which alternatives remain if the current regimen becomes difficult to tolerate or stops controlling the disease.

Sources and references: [1] [2]

Plan heart and lung safety checks

Some HER2-directed medicines can affect heart function, so baseline and follow-up heart assessment may be needed. ADCs have additional risks that differ by product. Trastuzumab deruxtecan can cause interstitial lung disease or pneumonitis, making new cough or breathlessness important to report promptly.

Tell the team about existing heart or lung disease and previous chest radiation. Ask which symptoms need urgent contact and which test results would lead to a pause or change. The safety plan should name the exact medicines being used.

Sources and references: [1]

Clarify the calendar and cumulative side effects

The overall schedule may include chemotherapy, ongoing anti-HER2 treatment, surgery, radiation and endocrine therapy for hormone receptor-positive disease. Their purposes and timing differ. A written calendar can help you arrange work, transport and family support.

Report fatigue, bowel symptoms or numbness rather than assuming they are unavoidable. Supportive treatment and dose adjustments can sometimes make a meaningful difference. If care moves between hospitals, obtain the treatment and cardiac monitoring records before the transfer.

Sources and references: [1]

Preparing a HER2 treatment review in Shanghai

Fudan University Shanghai Cancer Center has a breast cancer multidisciplinary service. A review can focus on the initial sequence, postoperative residual disease or the next line in metastatic care.

EastMedGo can help organize the inquiry with the full HER2 report, pathology, scans and previous drugs. Include heart assessment results when available. We can clarify record requirements and consultation logistics so the receiving team can address the treatment decision, with coordination costs discussed separately.

Sources and references: [3]

Common questions